Logo

AMST

Amesite Inc.

AMST

Amesite Inc. • NASDAQ
$2.35 ▲ 2.39% (+0.06)
Market Cap $10.77 M
52w High $6.27
52w Low $2.00
Dividend Yield 0%
P/E -2.84
Volume 4.25K
Outstanding Shares 4.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $94.296K ▲ $695.98K ▼ $-642.266K ▲ -681.117% ▲ $-0.14 ▲ $-581.826K ▲
Q4-2025 $55.759K ▲ $811.353K ▲ $-923.986K ▼ -1.657K% ▲ $-0.2 ▼ $-821.902K ▼
Q3-2025 $30.69K ▲ $617.903K ▼ $-663.418K ▲ -2.162K% ▲ $-0.16 ▲ $-562.909K ▲
Q2-2025 $12.76K ▲ $1.031M ▲ $-1.122M ▼ -8.79K% ▼ $-0.4 ▼ $-1.009M ▼
Q1-2025 $11.25K $820.319K $-908.045K -8.072K% $-0.34 $-789.77K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $1.83M ▼ $2.596M ▼ $427.637K ▲ $2.168M ▼
Q4-2025 $2.333M ▼ $3.097M ▼ $358.596K ▲ $2.739M ▼
Q3-2025 $2.859M ▲ $3.809M ▲ $210.954K ▼ $3.598M ▲
Q2-2025 $519.706K ▼ $2.136M ▼ $888.737K ▲ $1.247M ▼
Q1-2025 $1.435M $3.236M $843.003K $2.393M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-642.266K ▲ $-415.765K ▲ $-87.6K ▼ $0 $-503.365K ▲ $-503.365K ▲
Q4-2025 $-923.986K ▼ $-439.444K ▲ $-86.101K ▼ $0 ▼ $-525.545K ▼ $-525.545K ▲
Q3-2025 $-663.418K ▲ $-677.093K ▲ $-79.6K ▼ $3.096M ▲ $2.339M ▲ $-677.093K ▲
Q2-2025 $-1.122M ▼ $-850.448K ▼ $-64.599K ▲ $0 $-915.047K ▼ $-850.45K ▼
Q1-2025 $-908.045K $-488.263K $-148K $0 $-636.263K $-636.263K

Five-Year Company Overview

Income Statement

Income Statement Amesite looks like a very early‑stage, effectively pre‑revenue company. The reported figures show essentially no meaningful sales yet, but ongoing expenses that produce consistent losses. This is typical of a small software company still focused on building products and markets rather than scaling revenue. The pattern suggests the business model is not yet proven commercially, and future results will depend heavily on whether NurseMagic and related offerings can convert early interest into paying, recurring contracts.

Balance Sheet

Balance Sheet The balance sheet appears very thin, with a small asset base that has historically been mostly cash and no reported debt. That’s a plus in terms of not being burdened by lenders, but it also means there is only a limited financial cushion. With little in hard assets or retained capital, the company likely depends on raising new funds over time to support operations. This leaves it sensitive to market conditions and investor appetite for small, speculative tech names.

Cash Flow

Cash Flow Cash flows reflect a business that is spending on operations but not yet bringing in material cash from customers. Operating cash burn and negative free cash flow in prior periods point to ongoing funding needs. Capital spending is light, which fits a software model, but the key question is whether future cash outflows can be matched by growing, dependable inflows from enterprise healthcare clients. Until that happens, the company’s trajectory is closely tied to its ability to secure additional financing when needed.

Competitive Edge

Competitive Edge Competitively, Amesite is trying to build a niche within healthcare by focusing on nurses’ documentation and workflow pain points. NurseMagic has some promising elements: a mobile‑first experience, strong user feedback, and an all‑in‑one toolkit that goes beyond simple note‑taking. The company is also layering on intellectual property and benefiting from data that can improve its AI over time. However, it operates in a crowded and fast‑moving space where much larger health‑IT and AI players, as well as well‑funded startups, are also targeting clinical documentation and workflow. Its small size, early stage, and dependence on landing enterprise deals make execution and sales scaling the main competitive risks.

Innovation and R&D

Innovation and R&D Innovation is clearly the company’s strength. It has repurposed its AI platform from education into healthcare and built NurseMagic as a broad assistant for nurses, covering documentation, communication, clinical information, and wellness. The planned AI‑powered EMR for post‑acute care could significantly expand its addressable market if delivered successfully and integrated into existing clinical environments. The use of patents, data‑driven improvement, and potential extensions into areas like public safety training all point to an R&D‑driven culture. The main uncertainties are whether the team can move from compelling prototypes and apps to robust, widely adopted enterprise systems in a highly regulated, integration‑heavy healthcare environment.

Summary

Overall, Amesite is a high‑innovation, high‑uncertainty story. Financially, it looks like a pre‑revenue, loss‑making company with a slim balance sheet and ongoing cash burn, which implies reliance on external funding. Strategically, it is trying to carve out a defensible niche in nurse workflow and post‑acute care EMR using proprietary AI and a data‑rich platform. The future path will likely be shaped by a few key factors: whether it can win and retain enterprise healthcare customers, demonstrate real productivity gains and satisfaction among nurses, manage regulatory and integration hurdles, and secure enough capital to bridge the gap from product development to sustainable, recurring revenue. Investors and stakeholders would typically focus on evidence of commercial traction and the company’s ability to extend its early technological lead into a durable business model.

NEWS

October 30, 2025 · 6:30 AM UTC

Amesite Announces 69% QoQ Revenue Increase in Q2 2026 and Product Plans for Coming Months

Read more

September 11, 2025 · 6:30 AM UTC

Amesite Reports 63% Revenue Growth from NurseMagic™ Enterprise; Announces Launch of AI-Powered Government Form-Fill Automation to Reduce Reporting Burden

Read more